Treating Preterm Infants at Risk for Chronic Lung Disease with Dexamethasone Leads to an Impaired Quality of General Movements

Neonatology ◽  
2002 ◽  
Vol 82 (3) ◽  
pp. 155-158 ◽  
Author(s):  
Arend F. Bos ◽  
Jasmin Dibiasi ◽  
Ansje H. Tiessen ◽  
Klasien A. Bergman
Keyword(s):  
At Risk ◽  
Lung Disease ◽  
Preterm Infants ◽  
Chronic Lung Disease ◽  
General Movements ◽  
Impaired Quality

Effect on Growth of Two Different Dexamethasone Courses for Preterm Infants at Risk of Chronic Lung Disease

Pharmacology ◽  
1999 ◽  
Vol 59 (5) ◽  
pp. 266-274 ◽  
Author(s):  
Costantino Romagnoli ◽  
Enrico Zecca ◽  
Giovanni Vento ◽  
Luca Maggio ◽  
Patrizia Papacci ◽  
...  
Keyword(s):  
At Risk ◽  
Lung Disease ◽  
Preterm Infants ◽  
Chronic Lung Disease ◽  
Effect On Growth

The role of ASC signalling in preterm infants at risk of chronic lung disease of prematurity

2018 ◽  
Author(s):  
David Gallacher ◽  
Martha Triantafilou ◽  
Julian Marchesi ◽  
Kathy Trianafilou ◽  
Sailesh Kotecha
Keyword(s):  
At Risk ◽  
Lung Disease ◽  
Preterm Infants ◽  
Chronic Lung Disease

Qualitative assessment of general movements in high-risk preterm infants with chronic lung disease requiring dexamethasone therapy

1998 ◽  
Vol 132 (2) ◽  
pp. 300-306 ◽  
Author(s):  
Arend F. Bos ◽  
Albert Martijn ◽  
Roelie M. van Asperen ◽  
Mijna Hadders-Algra ◽  
Albert Okken ◽  
...  
Keyword(s):  
High Risk ◽  
Lung Disease ◽  
Preterm Infants ◽  
Chronic Lung Disease ◽  
Qualitative Assessment ◽  
Dexamethasone Therapy ◽  
General Movements

scholarly journals Pulmonary hypertension in chronic lung disease and hypoxia

2019 ◽  
Vol 53 (1) ◽  
pp. 1801914 ◽  
Author(s):  
Steven D. Nathan ◽  
Joan A. Barbera ◽  
Sean P. Gaine ◽  
Sergio Harari ◽  
Fernando J. Martinez ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Current State ◽  
Risk Of Mortality ◽  
Increased Risk ◽  
Oxygen Requirements ◽  
Impaired Quality

Pulmonary hypertension (PH) frequently complicates the course of patients with various forms of chronic lung disease (CLD). CLD-associated PH (CLD-PH) is invariably associated with reduced functional ability, impaired quality of life, greater oxygen requirements and an increased risk of mortality. The aetiology of CLD-PH is complex and multifactorial, with differences in the pathogenic sequelae between the diverse forms of CLD. Haemodynamic evaluation of PH severity should be contextualised within the extent of the underlying lung disease, which is best gauged through a combination of physiological and imaging assessment. Who, when, if and how to screen for PH will be addressed in this article, as will the current state of knowledge with regard to the role of treatment with pulmonary vasoactive agents. Although such therapy cannot be endorsed given the current state of findings, future studies in this area are strongly encouraged.

Sign in / Sign up

Export Citation Format

Share Document